Navigation Links
Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer
Date:3/23/2009

MALVERN, Pa., March 23 /PRNewswire/ -- Fujirebio Diagnostics, Inc., the premier cancer diagnostics company and the industry leader in cancer biomarker assays, today announced the appointment of Grady Barnes, Ph.D. as Chief Scientific Officer. Dr. Barnes comes to Fujirebio Diagnostics with 25 years of diagnostics experience. He has held various positions at Abbott and Meridian Bioscience, most recently as Vice President of Research & Development at Meridian Bioscience.

As Chief Scientific Officer, Dr. Barnes will be responsible for all scientific affairs including research and development, product development, process engineering and clinical and regulatory affairs. He will also assist in the selection of new product candidates and licensing opportunities for Fujirebio Diagnostics products.

"Dr. Barnes' extensive experience in diagnostics will be vital to sustaining Fujirebio Diagnostics' growth," says Paul Touhey, President and CEO of Fujirebio Diagnostics. "His expertise will support the growth and acceptance of biomarker assays in ovarian cancer, such as HE4, and help Fujirebio Diagnostics identify additional promising biomarkers in oncology."

Barnes received a Bachelor of Arts degree in natural sciences from Johns Hopkins University, and his Ph.D. in biochemistry from Florida State University. He has directed the commercialization of over 50 products, including diagnostic assay kits, hardware and software.

About Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is one of the group companies of Miraca Holdings, Inc., in Japan, set up in July 2005 to combine Fujirebio Inc., the leading in-vitro diagnostics company, and SRL, Inc., the top provider of clinical laboratory testing services in Japan. Fujirebio Diagnostics has a worldwide distribution network which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call

610-240-3800 or visit www.fdi.com.


'/>"/>
SOURCE JFK Communications, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
2. Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbotts Architect(R) Analyzers
3. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
4. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
5. Hypertension Diagnostics Announces Fiscal Year 2007 Results
6. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
7. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
10. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
11. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: